Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

NeoStem Divests its 51% Stake in Suzhou Erye Pharma

publication date: Jun 19, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
NeoStem will divest its 51% interest in its China subsidiary, Suzhou Erye Pharmaceutical, for $12.3 million in cash, selling it to the owners of the remaining 49% of the business. It will also cancel some of the shares and warrants it issued to acquire Erye Pharma in 2009. NeoStem will realize a loss of between $18 million and $22 million on the transaction. According to NeoStem, China’s clampdown on antibiotic use and price controls on generic antibiotics made the acquisition less profitable than it projected at the time of the original transaction. More details....

Stock Symbol: (NYSE: NBS)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...